Tech Company M&A Transactions
Carmenta Bioscience Acquisition
Carmenta Bioscience, operating out of Palo Alto, was acquired by Progenity. The companies did not announce specifics regarding acquisition price or deal terms.
Transaction Overview
Company Name
Acquired By
Announced On
4/30/2015
Transaction Type
M&A
Amount
Unknown
M&A Terms
Financial terms of the transaction were not disclosed by the companies.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
4240 Wilkie Way
Palo Alto, CA 94306
USA
Palo Alto, CA 94306
USA
Phone
Website
Email Address
Overview
Carmenta Bioscience, Inc., is a privately held medical technology company dedicated to improving maternal and fetal health. Spun-out of Stanford University School of Medicine in 2012, Carmenta Bioscience is currently developing a highly accurate, serum-based diagnostic test for preeclampsia.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Matthew Cooper
Chief Scientific Officer
Atul Butte
Co-Founder
Bruce Ling
Browse more venture capital transactions:
Prev: 4/30/2015: CRISPR Therapeutics venture capital transaction
Next: 4/30/2015: ThreatQuotient venture capital transaction
Share this article
Where The Data Comes From
We do our best to document every notable VC transaction. VC investment data records reported here come from publicly available VC deal announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs